Evaluate Vantage 2023 Preview: free to download now
After a tough time for many in biopharma, what does 2023 hold for the sector? Find out in our preview of the year ahead.
Medtech bleeds corporate venture cash
Overall venture investment in the sector remains steady, but the big strategics back off.
Full steam ahead at F2G
The UK developer has the launch of what could be the first in a new class of antifungals in its sights.
Venture investors keep the purse strings tight
Third-quarter numbers show that biopharma venture investments are firmly back in 2018 territory.
Trad device start-ups catch the cash
Young device makers were surprisingly appealing to VCs in the first half of 2022 – unless they were active in digital health.
Delfi aims for a cheaper liquid biopsy
With a fresh $225m in the bank, Delfi works towards a cut-price, next-generation lung cancer screen.
